Search Page

1

Cite

Share

Mesothelin-targeted CAR-T cell therapy for solid tumors.

Klampatsa A, Dimou V, Albelda SM. Klampatsa A, et al. Expert Opin Biol Ther. 2021 Apr;21(4):473-486. doi: 10.1080/14712598.2021.1843628. Epub 2020 Nov 12. Expert Opin Biol Ther. 2021. PMID: 33176519 Review.

Cite

Share

2

Cite

Share

Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy.

Hawkins ER, D'Souza RR, Klampatsa A. Hawkins ER, et al. Among authors: klampatsa a. Biologics. 2021 Apr 14;15:95-105. doi: 10.2147/BTT.S291768. eCollection 2021. Biologics. 2021. PMID: 33883875 Free PMC article. Review.

Cite

Share

3

Cite

Share

Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma.

Bughda R, Dimou P, D'Souza RR, Klampatsa A. Bughda R, et al. Among authors: klampatsa a. Immunotargets Ther. 2021 Aug 5;10:313-323. doi: 10.2147/ITT.S291767. eCollection 2021. Immunotargets Ther. 2021. PMID: 34386436 Free PMC article. Review.

Cite

Share

4

Cite

Share

Function of Human Tumor-Infiltrating Lymphocytes in Early-Stage Non-Small Cell Lung Cancer.

O'Brien SM, Klampatsa A, Thompson JC, Martinez MC, Hwang WT, Rao AS, Standalick JE, Kim S, Cantu E, Litzky LA, Singhal S, Eruslanov EB, Moon EK, Albelda SM. O'Brien SM, et al. Among authors: klampatsa a. Cancer Immunol Res. 2019 Jun;7(6):896-909. doi: 10.1158/2326-6066.CIR-18-0713. Epub 2019 May 3. Cancer Immunol Res. 2019. PMID: 31053597 Free PMC article.

Cite

Share

5

Cite

Share

Current Advances in CAR T Cell Therapy for Malignant Mesothelioma.

Klampatsa A, Albelda SM. Klampatsa A, et al. J Cell Immunol. 2020;2(4):192-200. doi: 10.33696/immunology.2.042. J Cell Immunol. 2020. PMID: 32914147 Free PMC article.

Cite

Share

6

Cite

Share

Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM).

Klampatsa A, Haas AR, Moon EK, Albelda SM. Klampatsa A, et al. Cancers (Basel). 2017 Sep 1;9(9):115. doi: 10.3390/cancers9090115. Cancers (Basel). 2017. PMID: 28862644 Free PMC article. Review.

Cite

Share

7

Cite

Share

Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes.

Klampatsa A, O'Brien SM, Thompson JC, Rao AS, Stadanlick JE, Martinez MC, Liousia M, Cantu E, Cengel K, Moon EK, Singhal S, Eruslanov EB, Albelda SM. Klampatsa A, et al. Oncoimmunology. 2019 Jul 13;8(9):e1638211. doi: 10.1080/2162402X.2019.1638211. eCollection 2019. Oncoimmunology. 2019. PMID: 31428531 Free PMC article.

Cite

Share

8

Cite

Share

CAR T-cell immunotherapy of MET-expressing malignant mesothelioma.

Thayaparan T, Petrovic RM, Achkova DY, Zabinski T, Davies DM, Klampatsa A, Parente-Pereira AC, Whilding LM, van der Stegen SJ, Woodman N, Sheaff M, Cochran JR, Spicer JF, Maher J. Thayaparan T, et al. Among authors: klampatsa a. Oncoimmunology. 2017 Aug 14;6(12):e1363137. doi: 10.1080/2162402X.2017.1363137. eCollection 2017. Oncoimmunology. 2017. PMID: 29209570 Free PMC article.

Cite

Share

9

Cite

Share

Precision-Cut Tumor Slices (PCTS) as an Ex Vivo Model in Immunotherapy Research.

Dimou P, Trivedi S, Liousia M, D'Souza RR, Klampatsa A. Dimou P, et al. Among authors: klampatsa a. Antibodies (Basel). 2022 Apr 6;11(2):26. doi: 10.3390/antib11020026. Antibodies (Basel). 2022. PMID: 35466279 Free PMC article. Review.

Cite

Share

10

Cite

Share

Analysis and Augmentation of the Immunologic Bystander Effects of CAR T Cell Therapy in a Syngeneic Mouse Cancer Model.

Klampatsa A, Leibowitz MS, Sun J, Liousia M, Arguiri E, Albelda SM. Klampatsa A, et al. Mol Ther Oncolytics. 2020 Jul 15;18:360-371. doi: 10.1016/j.omto.2020.07.005. eCollection 2020 Sep 25. Mol Ther Oncolytics. 2020. PMID: 32802940 Free PMC article.

Cite

Share